Aqix Limited Logo AQIX® Fluid Technology.
Designed-Developed-Patented-Manufactured.
The World's Only Synthetic Human Interstitial Fluid

Latest news:

AUG 2011

Aqix Limited patent for the intravenous application of AQIX® RS-I is granted in South Africa.

JUNE 2011

Aqix Limited is awarded a Research and Development Grant from the Technology Strategy Board for intravenous application of AQIX® RS-I.


Company History


DateActivity
2006 Res-Del International Ltd was renamed Aqix Limited following new investment funding and a new corporate board. Res-Del International Ltd was the incorporation of Res-Del Ltd, New Zealand
2005 Patent for AQIX® RS-I solution granted in EU/USA for organ perfusion and preservation.
2002-2005 Res-Del Ltd negotiated with a Organ Recovery Systems and Bowman Research (USA) to audit trial AQIX® RS-I solution for use as a hypothermic preservation and normothermic perfusion medium with human tissues and organs.
These trials proved successful with AQIX® RS-I being adopted as the data base perfusate in drug bioassay assessment of preserved, cadaver human donor organs (e.g., kidneys; lungs; livers; intestine) which were unsuitable for recipient transplantation.
2000 Res-Del International Ltd files patent on Res Del® RS-I solution for examination in EU/USA.